Salvia BioElectronics raises $60M Series B to commercialize VNS implant for chronic migraine
Summary
Salvia BioElectronics raised $60 million in a Series B to finish clinical development and prepare for commercial launch of their SALVIA implantable vagus nerve stimulation system for chronic migraine. The Netherlands-based company's device targets the cervical vagus nerve to prevent migraine attacks in high-frequency and chronic migraine patients who have failed multiple preventive medications. Migraine affects 1 billion people globally and is the leading cause of disability in adults under 50 — yet current device-based options are limited to CGRP antibody biologics and a single FDA-cleared VNS device (gammaCore). Salvia's implantable approach targets patients with the most severe, treatment-resistant migraine burden.
Why it matters
A $60M Series B for implantable VNS migraine prevention is the largest single round ever raised for a device-based migraine prevention company. Salvia's clinical program is specifically targeting the chronic migraine patients who have failed CGRP antibodies — the treatment-resistant tail of the migraine population where pharmacological options are exhausted. An implantable VNS that prevents rather than aborts migraines would be transformative for this population.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial